Clinical Trials Browser

Lymphoma, T-Cell, Peripheral × Nivolumab × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03586999 2024-10-29

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Phase 1/2 Completed

18 enrolled 14 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

131 enrolled 28 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT03927105 2024-03-18

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Completed

4 enrolled 11 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

RELATIVITY-069

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma